Meta-analyses have shown an increased risk of HF with the use of intermediate-acting CCBs from the dihydropyridine subgroup compared with the main alternative antihypertensive therapy, including β-blockers, diuretics, ACE inhibitors, or ARBs [118]. Here, ACE is linked to hydrops fetalis.